Zimbabwe has rejected a substantial American healthcare agreement worth 367 million US dollars (£272m) over five years over the United States' request for confidential biological samples.
This move came to light after a internal memorandum dated December was disclosed, which showed President Emmerson Mnangagwa believed the deal was "lopsided".
A government spokesman has since explained that the US was demanding access to biological samples for research and profit while refused to guarantee the benefits from any future vaccines.
"We will now turn to the challenging and unfortunate task of scaling back our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the United States had provided more than $1.9bn in health funding to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has urged further dialogue to find a agreement agreeable to all parties so the country's critical HIV programme can be sustained.
Wider Context
This rejection follows a similar situation in neighbouring Kenya, where a high court suspended a similar health funding agreement after legal challenges were filed about the safety of citizens' health data.
Since resuming the presidency last year, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
USAID had overseen aid for the American government, but Trump argued its spending was "inefficient" and his government was seeking direct bilateral agreements to enhance transparency and accountability.
According to statements, Sixteen nations in Africa have to date agreed to these new health pacts, representing more than $18.3bn of fresh investment.
Specifics of the Rejected Deal
The funds for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this collaboration could have provided immense benefits for Zimbabwean communities, especially the 1.2 million presently receiving antiretroviral therapy through American-funded initiatives," Tremont said.
However, official spokesman Nick Mangwana argued the arrangement was "unfair".
"Zimbabwe was being asked to provide its genetic material and health information for a long time, with no equivalent guarantee of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might result from that provided information," his statement read.
"Put simply, our country would provide the raw materials for scientific discovery with no assurance that the end products would be available to our citizens should a future pandemic arise."
National Interest and International Frameworks
Mangwana further pointed out that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one deals were upending systems already established via the global organization.
The spokesperson cited its Pathogen Access and Benefit Sharing scheme designed to deal with potential global health emergencies.
"This system is designed to guarantee that when a nation contributes its samples, the resulting advantages – such as medicines and cures – are distributed fairly, not commercialised solely by those with the capability to create them."
The government's concerns regarding the US deal "should not be misconstrued as opposition to America," he added.
"We welcome ongoing dialogue with our American counterparts on how subsequent collaboration might be designed in a way that honours the independence and interests of both nations."
Medical Community Response
Medical experts stated it recognised the government's concerns, but urged that negotiations need to persist since a large portion of the nation's HIV programmes were funded by foreign aid.
"If specific concerns exist, such as those relating to information security or agreement terms, these can often be addressed through technical clarification and mutually agreed protections," the group added.
This impasse emphasises the ongoing challenges between receiving much-needed international aid and protecting local interests in an increasingly data-driven world.